Characterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial

Parichehr Shamsrizi, Frederik Johannes Kramer, Marylyn Martina Addo, Anahita Fathi

Research output: Journal article (peer-reviewed)Journal article

1 Citation (Scopus)

Abstract

The development of an effective vaccine against SARS-CoV-2 marks one of the highest priorities during the ongoing pandemic. However, recruitment of participants for clinical trials can be challenging, and recruitment failure is among the most common reasons for discontinuation in clinical trials. From 20 May 2020, public announcements about a planned phase I trial of the vaccine candidate MVA-SARS-2-S against SARS-CoV-2 began, and interested individuals started contacting the study team via designated e-mail. All emails received from these individuals between 20 May 2020-30 September 2020 were assessed. Of the 2541 interested volunteers, 62% contacted the study team within three days after the first media announcement. The average age was 61 years (range 16-100), 48% of volunteers were female and 52% male. A total of 274, 186, and 53 individuals, respectively, reported medical pre-conditions, were health-care workers, or had frequent inter-person contacts. In conclusion, we report a high number of volunteers, with a considerable percentage stating factors for an elevated risk to acquire COVID-19 or develop severe disease. Factors such as media coverage and the perception of a disease as an acute threat may influence the individual's choice to volunteer for a vaccine trial. Our data provide first important insights to better understand reasons to participate in such trials to facilitate trial implementation and recruitment.

Original languageEnglish
Article number1208
JournalVaccines
Volume9
Issue number10
DOIs
Publication statusPublished - 19 Oct 2021

Fingerprint

Dive into the research topics of 'Characterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial'. Together they form a unique fingerprint.

Cite this